SPY756.95−0.38%QQQ684.96−0.79%BTC/USD73,312.28−0.83%DIA525.02+0.11%GLD362.20−0.81%TLT80.99+0.09%

Bio-Rad Laboratories Inc

BIONYSE

Trade with Public

$386.00

-0.48-0.12%

Last update: Nov 11, 4:00 PM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Bio-Rad Laboratories (BIO) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Bio-Rad Laboratories (BIO) stock.

Analyst Consensus — 4 Analysts

2Buy

2Hold

# Analysts4

Latest Upgrades and Downgrades for Bio-Rad Laboratories Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	RBC Capital	Dan Leonard	PT Raise	Outperform	$390→$440
—	RBC Capital	Dan Leonard	PT Raise	Outperform	$370→$390
—	Citigroup	Daniel Grosslight	PT Raise	Neutral	$300→$330
—	RBC Capital	Dan Leonard	PT Raise	Outperform	$320→$370
—	Wells Fargo	Evan Stampler	PT Raise	Equal-Weight	$310→$330
—	RBC Capital	Dan Leonard	Reinstates	Outperform	$320
—	Wells Fargo	Brandon Couillard	PT Cut	Equal-Weight	$320→$290
—	Citigroup	Patrick Donnelly	Downgrade	Buy→Neutral	$375→$300
—	Wells Fargo	Brandon Couillard	PT Cut	Equal-Weight	$340→$320
—	Citigroup	Patrick Donnelly	PT Raise	Buy	$350→$375
—	Wells Fargo	Brandon Couillard	PT Raise	Equal-Weight	$265→$340
—	RBC Capital	Conor McNamara	PT Raise	Outperform	$387→$409
—	Wells Fargo	Brandon Couillard	PT Raise	Equal-Weight	$245→$265
—	Wells Fargo	Brandon Couillard	PT Cut	Equal-Weight	$260→$245
—	UBS	Dan Leonard	PT Cut	Buy	$355→$310
—	Citigroup	Patrick Donnelly	PT Cut	Buy	$400→$350
—	RBC Capital	Conor McNamara	PT Cut	Outperform	$409→$392
—	Wells Fargo	Brandon Couillard	PT Cut	Equal-Weight	$320→$270
—	RBC Capital	Conor McNamara	PT Cut	Outperform	$430→$409
—	Citigroup	Patrick Donnelly	PT Cut	Buy	$450→$400

Bio-Rad Laboratories Inc

Bio-Rad Laboratories (BIO) Stock Price Target 2026

Latest Upgrades and Downgrades for Bio-Rad Laboratories Stock

Bio-Rad Laboratories (BIO) Stock Price Target 2026

Latest Upgrades and Downgrades for Bio-Rad Laboratories Stock

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $440

PRO
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $390

PRO
Citigroup Maintains Neutral on Bio-Rad Laboratories, Raises Price Target to $330

PRO
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $370

PRO
Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $330

PRO
RBC Capital Reinstates Outperform on Bio-Rad Laboratories, Announces $320 Price Target

People Also Watch

People Also Watch

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $440

PRO
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $390

PRO
Citigroup Maintains Neutral on Bio-Rad Laboratories, Raises Price Target to $330

PRO
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $370

PRO
Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $330

PRO
RBC Capital Reinstates Outperform on Bio-Rad Laboratories, Announces $320 Price Target

Bio-Rad Laboratories Inc

Bio-Rad Laboratories (BIO) Stock Price Target 2026

Latest Upgrades and Downgrades for Bio-Rad Laboratories Stock

Bio-Rad Laboratories (BIO) Stock Price Target 2026

Latest Upgrades and Downgrades for Bio-Rad Laboratories Stock

Analyst Ratings News

PRORBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $440

PRORBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $390

PROCitigroup Maintains Neutral on Bio-Rad Laboratories, Raises Price Target to $330

PRORBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $370

PROWells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $330

PRORBC Capital Reinstates Outperform on Bio-Rad Laboratories, Announces $320 Price Target

People Also Watch

People Also Watch

Analyst Ratings News

PRORBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $440

PRORBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $390

PROCitigroup Maintains Neutral on Bio-Rad Laboratories, Raises Price Target to $330

PRORBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $370

PROWells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $330

PRORBC Capital Reinstates Outperform on Bio-Rad Laboratories, Announces $320 Price Target

PRO
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $440

PRO
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $390

PRO
Citigroup Maintains Neutral on Bio-Rad Laboratories, Raises Price Target to $330

PRO
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $370

PRO
Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $330

PRO
RBC Capital Reinstates Outperform on Bio-Rad Laboratories, Announces $320 Price Target

PRO
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $440

PRO
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $390

PRO
Citigroup Maintains Neutral on Bio-Rad Laboratories, Raises Price Target to $330

PRO
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $370

PRO
Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $330

PRO
RBC Capital Reinstates Outperform on Bio-Rad Laboratories, Announces $320 Price Target